NVAF Management and Future Directions

PCE

English - May 26, 2022 14:05 - 20 minutes - 19 MB - ★★★★ - 6 ratings
Courses Education Science Life Sciences app education np education podcasts for credit app medicine pa education np medicine pa medicine ce podcasts app podcasts cme podcasts Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Strategies to Overcome SDOH in NVAF

Next Episode: Overview of SDOH in NVAF and CV-Related Outcomes

This podcast is the third in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Keith C. Ferdinand, MD, FACC, FAHA, details the effects of SDOH on anticoagulation prescribing in NVAF and provides an overview of areas for future study. Review the downloadable slideset and full program at: PCE.is/NVAF.

Contributors:

Program Director

Keith C. Ferdinand, MD, FACC, FAHA, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.

Faculty

David S. Kountz, MD, has no relevant conflicts of interest to report.

Laura Ross, PA-C, CLS, has no relevant conflicts of interest to report.